MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200 million upfront. The deal gives MSD exclusive rights to the ...
Nearly two years after Takeda pulled its US marketing application for a vaccine against dengue fever, MSD has advanced a rival shot into phase 3. The international MOBILIZE-1 trial is looking at a ...
If you’d like to fix or even diagnose anything involving electricity – whether it’s the energy that surges through a car, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback